Unique Treatment Raises Tricky Bioethical Issues

Yard, Delicia Honen
August 2010
Renal & Urology News;Aug2010, Vol. 9 Issue 8, p28
The article discusses tricky bioethical issues related to the treatment of prostate cancer. It mentions that despite the benefits of vaccine for advanced castration-resistant prostate cancer, the treatment is an extremely high cost. It tackles the bioethical issue of the Provenge, a treatment for prostate cancer.


Related Articles

  • Castrate-resistant prostate cancer. Black, Peter // Oncology Exchange;Aug2011, Vol. 10 Issue 3, p9 

    The article discusses the development of various treatments for castrate-resistant prostate cancer (CPRC). It reviews some of the treatments in treating patients with CPRC which include abiratorine, denosumab, and zoledronic acid. It highlights various breakthroughs in managing CPRC that...

  • Sipuleucel-T Suspension for Intravenous Infusion (Provenge). Elliott, William T.; Chan, James // Internal Medicine Alert;6/15/2010, Vol. 32 Issue 11, p85 

    The article provides information on Sipuleucel-T vaccine, a cellular immunotherapy suggested to treat prostate cancer.

  • Cancer vaccines: The hope is real. Shah, Monica // Drug Topics;3/10/2008, Vol. 152 Issue 4, p22 

    The article reports on various prostate cancer vaccines being examined by the U.S. Food and Drug Administration for its effectivity as of March 2008. The section features two cell-based prostate cancer vaccines, GVAX by Cell Genesys and sipuleucel-T by Dendreon. Jeffrey Schlom from the...

  • Androgen Deprivation Therapy for Localized Prostate Cancer. Kuritzky, Louis // Internal Medicine Alert;8/29/2008, Vol. 30 Issue 16, p128 

    The article reports on the androgen deprivation therapy (ADT) for localized prostate cancer (P-CA), the most common cancer among American men.

  • Notebook.  // FDA Consumer;Nov/Dec97, Vol. 31 Issue 7, p37 

    States that the combination of two prostate cancer therapies can improve the chances of survival. Survival rate using the therapies.

  • First cancer vaccine approved for use in people.  // New Scientist;5/8/2010, Vol. 206 Issue 2759, p5 

    The article discusses a prostate cancer vaccine called Provenge that has been approved by the U.S. Food and Drug Administration (FDA) for use in humans.

  • Prostate cancer multimodal therapy involvement in couple life: Open, Robotic and HIFU approach. Hirişcău, Elisabeta Ioana; Cosman, Doina; Coman, Ioan // Human & Veterinary Medicine;Dec2010, Vol. 2 Issue 2, p82 

    The diagnosis and treatment of prostate cancer often results in significant physical side-effects and associated psycho-social stressors that can interfere with the experience of sexual intimacy for couples. Our study aims to evaluate couple's sexual life and to determine any potential sexual...

  • A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Noguchi, Masanori; Moriya, Fukuko; Koga, Noriko; Matsueda, Satoko; Sasada, Tetsuro; Yamada, Akira; Kakuma, Tatsuyuki; Itoh, Kyogo // Cancer Immunology, Immunotherapy;Feb2016, Vol. 65 Issue 2, p151 

    This study investigated the effect of metronomic cyclophosphamide (CPA) in combination with personalized peptide vaccination (PPV) on regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC), and whether it could improve the antitumor effect of PPV. Seventy patients with metastatic...

  • Have side effects of PCa tx been underestimated? Overmyer, Mac // Urology Times;May98, Vol. 26 Issue 5, p45 

    Presents information on a study regarding the underestimation of the side effects of prostate cancer treatment. Complication of radical prostatectomy and radiotherapy for prostate cancer; Details on the study; Result of the study.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics